Xellia Pharmaceuticals has started building a stability and release-testing unit at its API facility in Budapest, Hungary that is designed to support increased output.
Cambridge Major Laboratories Europe (CMLE) is set to start commercial API manufacturing at its facility in the Netherlands after approval by Dutch regulators.
Intercell has killed development of its Travellers’ Diarrhoea Vaccine Patch after the product failed in clinical trials which will lead to job cuts and a dramatic reduction of R&D expenses.
Acambis has commenced clinical trials of its investigational
vaccine against Clostridium difficile (C. difficile) - a common
hospital-acquired infection, in which a new virulent strain has
emerged, causing sharp increases in the number...